Palmitoyl Tetrapeptide-7

CosmeticCosmetic matrikineExperimental

Also known as: Pal-GQPR, Rigin, Part of Matrixyl 3000

Palmitoyl Tetrapeptide-7 (also called Pal-GQPR or Rigin) is a cosmetic matrikine in the Matrix / Angiogenic class. Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling.

Calculate Dose

For research use only.

Key Facts

CAS
221227-05-0
Molecular Weight (MW)
≈694.9 g/mol
Half-life
Topical; systemic PK not established
FDA status
Not Approved
Evidence level
Limited Human Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
IL-6 / dermal inflammation (cosmetic models)

Research summary

Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trials1 reviewed source
  • Early or uncontrolled human studies2 reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Palmitoyl Tetrapeptide-7 profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Palmitoyl Tetrapeptide-7 dosage: no established human dose

Palmitoyl tetrapeptide-7 has no established human dosage. It is a cosmetic ingredient, often paired with palmitoyl tripeptide-1 as Matrixyl 3000. Its human studies test it in blends: one compared a peptide blend with placebo using skin imaging, and others are an uncontrolled eye-cream study and a three-person skin-permeation study.

Limited Human Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: Palmitoyl tetrapeptide-7 is the four-amino-acid sequence GQPR linked to palmitic acid and is used in anti-ageing cosmetics, usually in blends. Its human evidence is small studies of blends, which cannot isolate its effect. There is no human study of it given by injection, so no injectable amount, route or interval is established.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Palmitoyl Tetrapeptide-7
Human dosing establishedNo
RouteTopical (in all human studies)
Evidence levelLimited Human Evidence
Last reviewed2026-11-07

Human research reported

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Palmitoyl Tetrapeptide-7, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Placebo-controlled skin-imaging study — peptide blend (Mondon et al., 2015)Clinical trial · Placebo-controlled in vivo study of a two-peptide blend, with ex vivo method workPeople studied in vivo against placebo (number not stated in the indexed abstract)Not stated in the indexed abstract; a blend of palmitoyl oligopeptide and palmitoyl tetrapeptide-7Topical——By ultrasound the blend reduced the thickness of the low-echogenic band under the epidermis and improved its density; confocal microscopy showed better dermal matrix structure than placeboMondon P et al. Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using MALDI-MSI, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications. J Cosmet Dermatol. 2015.
Clinical study — multi-ingredient eye cream (Yang et al., 2024)Clinical trial · Clinical study of a multi-ingredient product; a control group is not stated in the abstractAdults using the eye cream (number not stated in the indexed abstract)Not stated in the indexed abstract; the cream combined a yeast/rice ferment filtrate, N-acetylneuraminic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7Topical (periorbital area)—12 weeksSkin hydration +28.12%, elasticity +18.81% and ultrasound collagen measure +54.99% at 12 weeks; reported as well toleratedYang F et al. Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream. Skin Res Technol. 2024.
Skin permeation in volunteers — Matrixyl 3000 serum (Trzaska et al., 2026)Clinical trial · Small skin-permeation study in people (no efficacy outcome)3 healthy womenSerum strength not stated in the indexed abstractTopical, then tape stripping of the stratum corneum—Single exposures of 0.5, 2 and 5 hoursBoth palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 were found through every layer of the stratum corneum, between the cells rather than inside them, at falling levels with depthTrzaska AH et al. Permeation behaviour of cosmetic actives into the human stratum corneum. Int J Pharm. 2026.

Where sources disagree

  • A percentage or ppm in a cream is a formulation strength, not a dose, and cannot be converted into an amount for injection.
  • Every human study found tests it alongside other peptides or actives, so the results cannot be credited to palmitoyl tetrapeptide-7 alone.

Sequence & molecular data

Sequence and molecular data for Palmitoyl Tetrapeptide-7
Molecular formulaC34H62N8O7
Molecular weight≈694.9 g/mol
CAS number221227-05-0
Half-lifeTopical; systemic PK not established
AppearanceWhite powder
FormulationTopical Cream
PubChem CID10078408
FDA UNIIQ41S464P1R
DrugBankDB14137

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling. Supplier and cosmetic studies describe reduced production of interleukin-6 by keratinocytes and fibroblasts after ultraviolet or inflammatory challenge. The rationale is that chronic low-grade inflammation contributes to matrix degradation in photoaged skin, so damping cytokine output is intended to slow that process rather than to stimulate collagen directly. It is most often formulated alongside palmitoyl pentapeptide-4, which acts on matrix synthesis, and most published data concerns the combination rather than the isolated ingredient.

Origin

Synthetic palmitoylated tetrapeptide.

Targets

IL-6 / dermal inflammation (cosmetic models)

Research statistics

20 PubMed publications · 15.8% human clinical research · 0 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Palmitoyl Tetrapeptide-7 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Palmitoyl Tetrapeptide-7
FDA statusNot Approved
AvailabilityOTC / Supplement
WADA (sport)Permitted
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Anti-inflammatory cosmetic claims

Palmitoyl Tetrapeptide-7 side effects

Palmitoyl Tetrapeptide-7 has only limited human data, so the list below is incomplete and its side-effect profile is not well established.

Side Effects

  • Irritation uncommon

Stacking

Common stacking partners

palmitoyl-tripeptide-1

Combinations that include Palmitoyl Tetrapeptide-7, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Palmitoyl Tetrapeptide-7: frequently asked questions

What is Palmitoyl Tetrapeptide-7?

Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.

How does Palmitoyl Tetrapeptide-7 work?

Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling. Supplier and cosmetic studies describe reduced production of interleukin-6 by keratinocytes and fibroblasts after ultraviolet or inflammatory challenge.

Is Palmitoyl Tetrapeptide-7 FDA approved?

No. Palmitoyl Tetrapeptide-7 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of Palmitoyl Tetrapeptide-7?

Reported half-life for Palmitoyl Tetrapeptide-7 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Palmitoyl Tetrapeptide-7 banned in sport?

Palmitoyl Tetrapeptide-7 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

What peptides are similar to Palmitoyl Tetrapeptide-7?

Compounds most often compared with Palmitoyl Tetrapeptide-7 include Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-5, Acetyl Hexapeptide-8 and Acetyl Octapeptide-3. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Palmitoyl Tetrapeptide-7 profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Palmitoyl Tetrapeptide-7 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →